Posted inAnesthesiology Diabetes & Endocrinology news

European Perioperative Diabetes Care: Significant Practice Variation Impacts 30-Day Recovery Outcomes

The MOPED study of over 6,000 European patients reveals significant international variations in perioperative diabetes management. Findings demonstrate that higher preoperative HbA1c levels and practice inconsistencies are linked to fewer days at home within 30 days of surgery, highlighting an urgent need for clinical harmonization.
Posted inCritical Care Neurology news

Rising Hospital Mortality and Escalating Rates of Life-Sustaining Therapy Withdrawal in Critically Ill TBI Patients: A 15-Year Analysis

A 15-year observational study of over 45,000 TBI patients reveals a significant increase in hospital mortality and a tripling of life-sustaining therapy withdrawal, alongside rising rates of hypoxaemia, raising urgent questions about ethical frameworks and neurocritical care management.
Posted inDiabetes & Endocrinology Internal Medicine news

Precision Diabetology Validated: Algorithm for SGLT2i and DPP4i Selection Performs Accurately Across Major UK Ethnicity Groups

A retrospective cohort study validates an algorithm for choosing between SGLT2 and DPP4 inhibitors across diverse UK ethnicity groups, confirming its accuracy for precision medicine while highlighting the necessity of minor recalibration to optimize performance in different populations.
Posted inHematology-Oncology news Oncology

MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment

The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep responses with initial ibrutinib-venetoclax, while sparing early responders from additional toxicity.
Posted inAllergy & Immunology Hematology-Oncology news

Precision Gene Correction via Prime Editing Restores NADPH Oxidase Activity in Patients with p47phox-Deficient Chronic Granulomatous Disease

A Phase 1/2 clinical trial demonstrates that PM359, an autologous prime-edited CD34+ cell therapy, successfully corrects the delGT mutation in NCF1, restoring essential microbicidal function in patients with p47-CGD without the off-target risks associated with traditional CRISPR-Cas9.
The SEIZURE Score Faces Global Challenges: International Validation Highlights Geographic Disparities in Predicting Encephalitis Seizures
Posted inInfectious Diseases Neurology news

The SEIZURE Score Faces Global Challenges: International Validation Highlights Geographic Disparities in Predicting Encephalitis Seizures

An international evaluation of the SEIZURE score reveals limited global predictive power for acute seizures in encephalitis. While the tool performs well in Western Europe, particularly Portugal, its utility elsewhere is hampered by etiological diversity and diagnostic limitations.
Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia
Posted inHematology-Oncology news Oncology

Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia

Recent clinical trials demonstrate the rapid evolution of CD7-targeted CAR T-cell therapies. From donor-derived models to universal base-edited cells, these innovations offer high remission rates and a viable bridge to transplant for patients with relapsed T-cell acute lymphoblastic leukemia.
Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia
Posted inHematology-Oncology Internal Medicine news

Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia

The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thrombocytopenia (ITP) compared to eltrombopag alone.
Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention
Posted inHematology-Oncology news Oncology

Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention

The phase 3 MajesTEC-3 trial demonstrates that combining teclistamab with daratumumab significantly extends progression-free survival compared to standard therapies in patients with relapsed or refractory multiple myeloma, achieving high rates of complete response and minimal residual disease negativity.
Ketamine vs. Etomidate: Does Your Choice of Induction Agent Influence Mortality in the Critically Ill?
Posted inAnesthesiology Critical Care news

Ketamine vs. Etomidate: Does Your Choice of Induction Agent Influence Mortality in the Critically Ill?

This article explores recent evidence comparing ketamine and etomidate for rapid sequence intubation. While new cohort data suggests a mortality benefit for ketamine, meta-analyses of randomized trials show clinical equipoise, highlighting the complex trade-offs between adrenal suppression and hemodynamic stability.